Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Assessment of the immune response to tumors is growing in importance as the prognostic
implications of this response are increasingly recognized, and as immunotherapies are …

Chronic inflammation promotes the development of several types of solid cancers and might
contribute to prostate carcinogenesis. This hypothesis partly originates in the frequent …

Background Prostate cancer (PCa) is one of the most frequently diagnosed cancers in the
world. Emerging evidence suggests that inflammatory cells such as M2 macrophages and …

Prostate cancer remains the most frequently diagnosed cancer in men in North America, and
despite recent advances in treatment patients with metastatic disease continue to have poor …

The prostate gland produces prostatic fluid, high in zinc and citrate and essential for the
maintenance of spermatozoa. Prostate cancer is a common condition with limited treatment …

A key challenge in the clinical management and cause of treatment failure of prostate cancer
(PCa) is its molecular, cellular and clinical heterogeneity. Modelling systems that fully …

The continuous remodeling of the tumor microenvironment (TME) during prostate
tumorigenesis is emerging as a critical event that facilitates cancer growth, progression and …

Castration-resistant prostate cancer (CRPC) is associated with a poor prognosis and poses
considerable therapeutic challenges. Recent genetic and technological advances have …

Improved risk stratification is needed for patients with localized prostate cancer. This study
characterized and assessed the prognostic potential of distinct immune cell infiltration …